4/A//SEC Filing
Sandercock Colin 4/A
Accession 0001209191-20-045921
CIK 0001645460other
Filed
Aug 9, 8:00 PM ET
Accepted
Aug 10, 4:03 PM ET
Size
9.6 KB
Accession
0001209191-20-045921
Insider Transaction Report
Form 4/AAmended
Sandercock Colin
SVP, GENERAL COUNSEL
Transactions
- Sale
Common Stock
2020-08-05$20.00/sh−13,374$267,480→ 17,125 total - Exercise/Conversion
Common Stock
2020-08-05$7.50/sh+13,374$100,305→ 30,499 total - Exercise/Conversion
Stock Option (right to buy)
2020-08-05−13,374→ 130,000 totalExercise: $7.50Exp: 2024-12-27→ Common Stock (13,374 underlying)
Footnotes (4)
- [F1]This Form 4 amends and restates the original Form 4 filed on August 7, 2020 (the "Original Form 4") to include 100 Stock Options and shares of Common Stock that were omitted from the Original Form 4 due to clerical error.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- [F4]These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018.
Documents
Issuer
Cue Biopharma, Inc.
CIK 0001645460
Entity typeother
Related Parties
1- filerCIK 0001724870
Filing Metadata
- Form type
- 4/A
- Filed
- Aug 9, 8:00 PM ET
- Accepted
- Aug 10, 4:03 PM ET
- Size
- 9.6 KB